Boston Scientific Receives Approval – Analyst Blog

Boston Scientific Corporation (BSX) recently received U.S. Food and Drug Administration (FDA) approval for its Genesys HTA System for the treatment of menorrhagia. The new product is an endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. Genesys HTA System earlier received the CE Mark approval to market the product in Europe in January 2010.

 

The Genesys HTA System comprises a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface. Several technology upgrades improves the operating performance of the system.

 

We think that the new product will be widely accepted by physicians as a result of the enhanced features. This will boost Boston Scientific’s top-line.

 

The Genesys HTA System represents Boston Scientific’s next generation of endometrial system. This in turn strengthens the company’s portfolio of endometrial ablation products for the treatment of menorrhagia. It has been estimated that roughly ten million women in the U.S. suffer from Menorrhagia. 

 

Boston Scientific manufactures medical devices and products used in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. The primary competitors are Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).

 

Presently, we have a ‘Neutral’ recommendation on Boston Scientific.